Dr. Gendelman is credited in co-developing ultra long antiretroviral medicines and in demonstrating the role of brain immunity in neural cell damage. The consequent pharmacologic and immune transformative therapeutics were aimed at preventing, treating, slowing, or reversing infectious and degenerative neural maladies. He has authored more than 600 peer-reviewed publications, edited 12 books and monographs, holds 182 patents, is the editor-in-chief and founder of the Journal of Neuroimmune Pharmacology (until 2021) and the NeuroImmune Pharmacology and Therapy, along with service on 15 editorial boards, national and international scientific review and federal and state committees. He has been an invited lecturer to more than 300 scientific seminars and symposia and the recipient of numerous local, national and international honors. He enjoys a current Hirsch Index of 122, included amongst a selective scientific group listed on highly cited.com as one of the top-cited scientists in his field.